Platelet: Transporter of vascular endothelial growth factor

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2187-2190

  Verheul, Henk M W ^a   Hoekman, Klaas ^a   Luykx De Bakker, Sylvia ^a   Eekman, Cornelis A ^a   Folman, Claudia C ^a   Broxterman, Henk J ^a   Pinedo, Herbert M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CORRELATION FUNCTION; DIAGNOSTIC VALUE; HUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; TUMOR; TUMOR BLOOD FLOW; TUMOR GROWTH; WOUND HEALING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOTHELIAL GROWTH FACTORS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOKINES; PLATELET ACTIVATION; REFERENCE VALUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031426425     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
2. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-354, 1996.
3. Weidner, N., Semple, J. P., Welch, J. R., and Folkman, J. Tumor angiogenesis: a new significant and independent prognostic indicator in early breast carcinoma. J. Natl. Cancer Inst., 84: 1875-1887, 1992.
4. Horak, E. R., Leek, R., Klenk, N., Lejeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K., and Harris, A. L. Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies as indicator of node metastases and survival in breast cancer. Lancet, 340: 1120-1124, 1992.
5. Gasparini, G., and Harris, A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol., 13: 765-782, 1995.
6. Gasparini, G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the vicenza studies. Eur. J. Cancer, 14: 2485-2493, 1996.
7. Klagsburn, M., and D'Amore, P. A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev., 3: 259-270, 1996.
8. Toi, M., Inada, K., Suzuki, H., and Tominaga, T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res. Treat., 36: 193-204, 1995.
9. Gasparini, G., Toi, M., Gion, M., Verderio, P., Dittadi, R., Hanatani, M., Matsubara, I., Vinante, O., Bonoldi, E., Boracchi, P., Gatti, C., Suzuki, H., and Tominaga, T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst., 89: 139-147, 1997.
10. Mohle, R., Green, D., Moore, M. A., Nachman, R. L., and Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci., 94: 663-668, 1997.
11. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., and Folkman, J. Elevated concentrations of the angiogenic peptide basic fibroblast growth factor in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst., 85: 241-242, 1993.
12. Yamamato, Y., Toi, M., Kondo, S., Matsumoto, T., Suzuki, H., Kitamura, M., Tsuruta, K., Taniguchi, T., Okamoto, A., Mori, T., Yoshida, M., Ikeda, T., and Tominaga, T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res., 2: 821-826, 1996.
13. Pinedo, H. M., Luykx, S., van Hensbergen, S., Hoekman, K., Honkoop, A., van Diest, P., and Wagstaff, J. Extended neo-adjuvant high dose chemo-immunotherapy followed by surgery and radiotherapy for locally advanced breast cancer: a general proposal for high risk primary tumors. Proc. Am. Assoc. Cancer Res., 38: 2925, 1997.
14. Hoekman, K., Wagstaff, J., van Groeningen, C. J., Vermorken, J. B., Boven, E., and Pinedo, H. M. Effects of recombinant human granulocyte macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J. Natl. Cancer Inst., 83: 1546-1552, 1991.
15. Modderman, P. W., Huisman, H. G., van Mourik, I. A., and von den Borne, A. E. G. K. A monoclonal antibody to the human platelet glycoprotein IIb/IIIa complex induces platelet activation. Thromb. Haemostasis, 60: 68-74, 1988.
16. Munn, R. K., Gagliardi, A., Stepick-Biek, P., King, R., and Collins, D. Serum vascular endothelial growth factor in women with breast cancer. Proc. Am. Assoc. Cancer Res., 37: 1298, 1996.
17. Heits, F., Katschinski, D. M., Wiedemann, G. J., Weiss, C., and Jelkmann, W. Serum vascular endothelial growth factor, a prognostic indicator in sarcoma and carcinoma patients. Int. J. Oncol., 10: 333-337, 1997.
18. Kondo, S., Asano, M., Matsuo, K., Ohmori, I., and Suzuki, H. Vascular endothelial growth factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta, 1221: 211-214, 1994.
19. Salven, P., Maenpaa, H., Orpana, A., Alitalo, K., and Joensuu, H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res., 3: 647-651, 1997.
20. Harker, L. A., and Slichter, S. J. Platelet and fibrinogen consumption in man. N. Engl. J. Med., 287: 999-1005, 1972.
21. Schafer, A. I. The platelet life cycle: normal function and qualitative disorders. In: R. I. Handin, H. S. Lux, and T. P. Stossel (eds.), Blood: Principles and Practice of Hematology, pp. 1095-1126. Philadelphia: J. B. Lippincott Co., 1995.
22. Folkman, J. Tumor angiogenesis. In: J. Mendelsohn, P. M. Howley, M. A. Israel, and L. A. Liotta (eds.), The Molecular Basis of Cancer, pp. 206-232. Philadelphia: W. B. Saunders Co., 1995.
23. Gasic, G., Gasic, T., and Stewart, C. C. Antimetastatic effects associated with platelet reduction. Proc. Natl. Acad. Sci. USA, 61: 46-52, 1968.
24. Pearlstein, E., Ambrogio, C., and Karpatkin, S. Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice. Cancer Res., 44: 3884-3887, 1964.
25. Hilgard, P., Schulte, H., Wetzig, G., Schmitt, G., and Schmidt, C. G. Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL). Br. J. Cancer, 35: 78-85, 1977.
26. Hohn, K. V., Tang, D. G., and Crissman, J. D. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev., 11: 325-351, 1992.
27. Dvorak, H. F. Tumors: wounds that do not heal. N. Engl. J. Med., 315: 1650-1659, 1986.
28. Pedersen, L. M., and Milman, N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur. Respir. J., 9: 1826-1830, 1996.
29. Young, M. R., Lozano, Y., Djordjevic, A., Devata, S., Matthews, J., Young, M. E., and Wright, M. A. Granulocyte macrophage colony-stimulating factor stimulates the metastatic properties of Lewis lung carcinoma cells through a protein kinase A signal-transduction pathway. Int. J. Cancer, 53: 667-671 1993.
30. Kaushansky, K. Thrombopoietin: the primary regulator of platelet production. Blood, 86: 419-431, 1995.
31. Kakkar, A. K., and Williamson, R. C. N. Thromboprophylaxis in malignant disease. Br. J. Surg., 82: 724-725, 1995.